2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
484
Carcinoma, Non-Small-Cell Lung
440
Prostatic Neoplasms
292
Lung Neoplasms
170
Stomach Neoplasms
140
Neoplasms
114
Squamous Cell Carcinoma of Head and Neck
109
Neoplasm Metastasis
97
Head and Neck Neoplasms
96
Esophageal Neoplasms
71
Ovarian Neoplasms
57
Pancreatic Neoplasms
42
Urinary Bladder Neoplasms
39
Sarcoma
39
Nasopharyngeal Carcinoma
36
Carcinoma, Squamous Cell
30
Triple Negative Breast Neoplasms
28
Carcinoma, Ovarian Epithelial
28
Adenocarcinoma of Lung
27
Adenocarcinoma
27
Esophageal Squamous Cell Carcinoma
25
Parkinson Disease 4, Autosomal Dominant Lewy Body
23
Carcinoma, Transitional Cell
23
Adenocarcinoma Of Esophagus
23
Breast Neoplasms, Male
22
Recurrence
21
Unspecified Adult Solid Tumor, Protocol Specific
20
Inflammatory Breast Neoplasms
20
Fallopian Tube Neoplasms
20
Melanoma
18
Interventions
Carboplatin
15
Pemetrexed
8
Paclitaxel
6
pembrolizumab
5
osimertinib
4
atezolizumab
4
Gemcitabine
4
Erlotinib Hydrochloride
4
entinostat
3
durvalumab
3
Cisplatin
3
selpercatinib
2
pralsetinib
2
camrelizumab
2
apatinib
2
Vinorelbine
2
Radiosurgery
2
Nivolumab
2
Injections
2
Gefitinib
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
toripalimab
1
taletrectinib
1
sotorasib
1
sintilimab
1
repotrectinib
1
pegylated granulocyte colony-stimulating factor
1
patritumab
1
necitumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thoracic Neoplasms
×
Docetaxel
×
Clear all
NCT03402048
2020-11-04
EPIC
University of Turin, Italy
Phase 3
Unknown
567 enrolled